文献速递白血病

靶向AXL激酶使急性髓系白血病干细胞/祖细胞对venetoclax治疗敏感

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia.
PubMed 文献 · Blood · 2021-01-01

该研究显示AML患者细胞中GAS6/AXL轴高度激活,尤其在干/祖细胞中;开发的选择性AXL抑制剂在PDX模型中有效,且与venetoclax联用呈强协同效应。机制上AXL抑制靶向代谢脆弱性并抑制线粒体氧化磷酸化。

要点

  • AML干/祖细胞中GAS6/AXL轴高度激活。
  • 选择性AXL抑制剂在AML PDX模型中显示疗效。
  • AXL抑制与venetoclax联用具强协同效应。

核心结论

  • 靶向AXL可增敏AML干/祖细胞对venetoclax的治疗反应。

研究设计与样本

  • 临床前研究,使用AML患者来源异种移植(PDX)模型及体外实验。

主要发现

  • AML患者细胞中GAS6/AXL轴高度激活,尤其干/祖细胞。
  • AXL抑制剂与venetoclax在体外和PDX模型中呈强协同效应。
  • AXL抑制单用或联用venetoclax抑制线粒体氧化磷酸化。

临床怎么用

  • AXL抑制剂联合venetoclax可能成为靶向AML干/祖细胞的新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The abundance of genetic abnormalities and phenotypic heterogeneities in acute myeloid leukemia (AML) poses significant challenges to the development of improved treatments. Here, we demonstrated that a key growth arrest-specific gene 6/AXL axis is highly activated in cells from patients with AML, particularly in stem/progenitor cells. We developed a potent selective AXL inhibitor that has favorable pharmaceutical properties and efficacy against preclinical patient-derived xenotransplantation (PDX) models of AML. Importantly, inhibition of AXL sensitized AML stem/progenitor cells to venetoclax treatment, with strong synergistic effects in vitro and in PDX models. Mechanistically, single-cell RNA-sequencing and functional validation studies uncovered that AXL inhibition, alone or in combination with venetoclax, potentially targets intrinsic metabolic vulnerabilities of AML stem/progenitor cells and shows a distinct transcriptomic profile and inhibits mitochondrial oxidative phosphorylation. Inhibition of AXL or BCL-2 also differentially targets key signaling proteins to synergize in leukemic cell killing. These findings have a direct translational impact on the treatment of AML and other cancers with high AXL activity.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Niu X, Rothe K, Chen M, et al. Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia. Blood. 2021. PMID: 33786587. doi:10.1182/blood.2020007651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。